The Health Resources and Services Administration’s proposed rule that would establish an administrative dispute resolution process for the 340B Drug Pricing Program “is an important first step for 340B hospitals and clinics that have been overcharged for drugs purchased through the program,” but there are several areas in which the rule could be amended, AHA said today. Specifically, the AHA urged HRSA to develop a “fast-track process” to provide 340B hospitals and other covered entities access to 340B drug ceiling prices, which “would help ensure a level-playing field in the dispute resolution process,” AHA Executive Vice President Tom Nickels said in a comment letter on the proposed rule. Among other proposals, AHA also commented on the ADR panel composition and decisions; information requests; and claims initiation and consolidation.

Related News Articles

Headline
The Centers for Medicare…
Headline
The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose…
Headline
The AHA today responded to a RAND Corporation study that found that certain prices paid to hospitals by private health plans are high relative to Medicare and…
Headline
A federal district court judge yesterday ruled that the Department of Health and Human Services would get "first crack at crafting appropriate remedial…
Headline
The Centers for Medicare…
Headline
Reps. Rosa DeLauro, D-Conn., and Jan Schakowsky, D-Ill., this week introduced the Medicare for America Act, legislation that would create a national health…